Recent advances in polymyositis
- PMID: 6203872
- DOI: 10.1007/BF02043966
Recent advances in polymyositis
Abstract
The most typical clinical features of polymyositis (PM), the criteria of diagnosis and principles of treatment are outlined. An inflammatory disease of muscle, PM also frequently affects other organs such as the skin and hence the name dermatomyositis. The principal cardiac symptom is a peculiar disturbance of atrioventricular conduction, correlated with a specific anti-Ro autoantibody, present in 25% of patients. The etiology of PM is as yet unknown, although there is evidence for an autoimmune pathogenesis. It is frequently found in association with other immune-mediated diseases such as myasthenia gravis, pemphigus, immune-complex vasculitis and Sjogren syndrome. Laboratory investigations show hypergammaglobulinemia, a decrease of complement factors C3 and C4 and the presence of circulating immune complexes in 70% of patients. Very frequent, especially in cases of dermatomyositis, is a histologically detectable accumulation of IgG and complement in the walls of the intramuscular venous vessels. Cell-mediated hypersensitivity, emphasised formerly as highly significant in PM, has not been confirmed. The presence of specific antimyoglobin lymphocyto-toxicity, once considered to be the hallmark of muscle degeneration in PM, has been excluded by a number of laboratories. In a personal series of patients with various clinical forms of PM a severe loss of suppressor/cytotoxic lymphocytes was found in the peripheral blood and a relative increase in the first subset. These results support the hypothesis that a serious disturbance of immunoregulation is present in PM and is the cause of a multitude of immunological anomalies, the characterisation of which is under study.
Similar articles
-
[The polymyositis-dermatomyositis complex: current studies of the etiopathogenesis and notes on therapy].Clin Ter. 1981 Jun 30;97(6):631-51. Clin Ter. 1981. PMID: 7023806 Review. Italian. No abstract available.
-
Clinical implications of autoantibody screening in patients with autoimmune myositis.Autoimmunity. 2006 May;39(3):217-21. doi: 10.1080/08916930600622645. Autoimmunity. 2006. PMID: 16769655
-
Pathogenic aspects of dermatomyositis, polymyositis and overlap myositis.Presse Med. 2011 Apr;40(4 Pt 2):e209-18. doi: 10.1016/j.lpm.2010.12.013. Epub 2011 Mar 3. Presse Med. 2011. PMID: 21376512 Review.
-
[Cellular immunity and the autoantibody system in polymyositis and dermatomyositis].Lijec Vjesn. 1991 Mar-Apr;113(3-4):95-9. Lijec Vjesn. 1991. PMID: 1890925 Review. Croatian.
-
Sjögren's syndrome and polymyositis or dermatomyositis.Arch Neurol. 1982 Mar;39(3):157-63. doi: 10.1001/archneur.1982.00510150027007. Arch Neurol. 1982. PMID: 7039564
Cited by
-
Autoimmunity in amyotrophic lateral sclerosis: past and present.Neurol Res Int. 2011;2011:497080. doi: 10.1155/2011/497080. Epub 2011 Aug 1. Neurol Res Int. 2011. PMID: 21826267 Free PMC article.
-
Pregnancy outcome in idiopathic inflammatory myopathy.Rheumatol Int. 2007 Mar;27(5):435-9. doi: 10.1007/s00296-006-0239-8. Rheumatol Int. 2007. PMID: 17033833
-
Anti-Ro(SSA) and anti-La(SSB) antibodies in autoimmune rheumatic diseases.Clin Rev Allergy. 1994 Fall;12(3):253-74. doi: 10.1007/BF02802321. Clin Rev Allergy. 1994. PMID: 7804958 Review. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous